SOUTHWEST ONCOLOGY GROUP (UTAH)

我们计划的目标是： 开展多学科协作临床研究 人类恶性疾病的管理。这项计划涉及 参加内科肿瘤学、外科肿瘤学、放射肿瘤学 和病理学。加州大学西南肿瘤学小组项目 犹他州在过去的四年里有效地继续了最低限度的 NCI的支持，通过广泛使用机构资金来维持 充分参与。 几次教员变动导致了我们SWOG的重组 领导力。参与这一项目的调查人员代表 伊利诺伊大学临床研究的最强领域 犹他州。随着这些领域的发展，我们计划推出由此产生的新的 计划进入西南肿瘤学小组。具体来说，这些措施包括： 积极的骨髓移植计划的发展；外科 肿瘤学，癌症免疫治疗的新领先者，补充以前 IL-2疫苗治疗计划；神经方面的持续发展- 肿瘤学专注于寻找与疾病相关的基因改变 治疗结果；在病理学方面，生物学方面的重大集体努力 强调与疾病反应的相关性，这将是 由犹他州的实验室研究补充，测量胞苷 三磷酸合成酶活性；在放射肿瘤学中， 在热疗结合放射治疗和 化疗。遗传学和流行病学方面的机构优势 涉及结肠癌和家族性息肉以及增生性息肉 乳腺疾病和家族性前列腺癌将整合到 该小组建议进行的化学预防研究。

Objectives of our program are: To conduct multidisciplinary collaborative clinical studies in the management of malignant disease in humans. This program involves participants in medical oncology, surgical oncology, radiation oncology and pathology. The Southwest Oncology Group Program at the University of Utah has effectively continued over the past four years with minimal support from NCI by extensively using institutional funds to maintain a full level of participation. Several faculty changes have led to a reorganization of our SWOG leadership. The investigators participating in this program represent the strongest areas of the clinical investigations at the University of Utah. As these areas develop, we plan to introduce the resulting new programs into the Southwest Oncology Group. Specifically, these include: the development of an active bone marrow transplant program; in surgical oncology, new leadership in cancer immunotherapy which supplements prior programs in IL-2 with vaccine therapy; continuing developments in neuro- oncology focusing on the search for gene alterations correlating with therapy outcome; in pathology, a significant group effort in the biology of leukemias emphasizing correlations to disease response which will be supplemented by laboratory studies at Utah measuring cytidine triphosphate synthetase activity; and in radiation oncology, a substantial expertise in hyperthermia combined with radiation and chemotherapy. The institutional strengths in genetics and epidemiology involving colon cancer and familial polyps as well as proliferative breast disease and familial prostate cancer will be integrated into proposed chemoprevention studies in the group.